

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vital BioTech Holdings Limited

維奧生物科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1164)

PROPOSED CHANGE OF COMPANY NAME

Subject to the passing of a special resolution approving the change of company name, the Company proposes to change the name of the Company to “Vital Pharmaceutical Holdings Limited 維奧醫藥控股有限公司”.

PROPOSED CHANGE OF COMPANY NAME

Subject to the passing of a special resolution approving the change of company name to be proposed at the extraordinary general meeting to be held by Vital BioTech Holdings Limited (the “**Company**”), the Company proposes to change its name to “Vital Pharmaceutical Holdings Limited 維奧醫藥控股有限公司”.

The directors (the “**Directors**”) believe that the proposed new name will better reflect the Group’s broaden investment strategies, including but not limited to, its undergoing acquisition of Sichuan Hengtai Pharmaceutical Company Limited which is engaged in the sale and distribution of pharmaceutical products in China, details of which have been disclosed in the Company’s announcement dated 12 November 2007. The Directors (including the independent non-executive Directors) consider that the proposed change of name of the Company is in the interest of the Company and the shareholders (the “**Shareholders**”) as a whole.

Upon the change of company name becoming effective, all existing share certificates bearing the current name of Vital BioTech Holdings Limited 維奧生物科技控股有限公司 will continue to be evidence of title to the shares and will continue to be valid for trading, settlement and registration purposes and the rights of the Shareholders will not be affected as a result of the change of company name. Should the change of company name become effective, any issue of share certificates thereafter will be in the new company name and the securities of the Company will be traded on The Stock Exchange of Hong Kong Limited in the new name.

Further announcement will be made by the Company when the change of company name becomes effective and the relevant trading arrangement (if any) as a result of the change of company name.

The circular containing the notice of extraordinary general meeting to approve the change of company name and further information regarding change of company name will be sent to the Shareholders of the Company as soon as practicable.

By order of the Board
Vital BioTech Holdings Limited
Tao Lung
Chairman

Hong Kong, 4 February 2008

As at the date of this announcement, the Board comprises six executive Directors: Mr. Tao Lung, Mr. Huang Jianming, Mr. Shen Songqing, Mr. Liu James Jin, Mr. Xu Xiaofan and Madam Guo Lin, and three independent non-executive Directors: Mr. Lui Tin Nang, Mr. Lee Kwong Yiu and Mr. Chong Cha Hwa.